Open AccessErythrocytes of patients with paroxysmal nocturnal haemoglobinuria acquire resistance to complement attack by purified 20‐kD homologous restriction factor
Author(s) -
OKADA N.,
HARADA R.,
OKADA H.
Publication year - 1990
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/j.1365-2249.1990.tb06449.x
Subject(s) - homologous chromosome , cd59 , immunology , decay accelerating factor , monoclonal antibody , complement system , biology , paroxysmal nocturnal hemoglobinuria , antibody , genetics , gene
SUMMARY A 20‐kD homologous restriction factor (HRF20) which is a membrane inhibitor of the terminal stage of human complement action can be detected by the monoclonal antibody IF5, and is deficient on abnormal erythrocytes as well as leucocytes from patients with paroxysmal nocturnal haemoglobinuria (PNH). The erythrocytes of PNH patients significantly improved their resistance to homologous complement after adsorption of purified HRF20.